132664-85-8

Usage

Uses

Used in Flavor and Fragrance Industry:
2-(AMINOMETHYL)-5-METHYLPYRAZINE is used as a flavoring agent for imparting a meaty, roasted, and nutty aroma to various products, enhancing the sensory experience of consumers.
Used in Pharmaceutical and Fine Chemicals Synthesis:
2-(AMINOMETHYL)-5-METHYLPYRAZINE is used as a building block in the synthesis of pharmaceuticals and other fine chemicals, contributing to the development of new compounds with potential therapeutic applications.
Used in Medicinal Chemistry Research:
2-(AMINOMETHYL)-5-METHYLPYRAZINE is used as a subject of interest in medicinal chemistry research for its potential anti-cancer and anti-inflammatory properties, indicating its potential as a lead compound for the development of novel therapeutic agents.

InChI:InChI=1/C6H9N3/c1-5-3-9-6(2-7)4-8-5/h3-4H,2,7H2,1H3

Upstream product

• 123-32-0 2,5-dimethyl-pyrazine 
• 98006-91-8 5-methylpyrazine-2-carbonitrile 

Downstream Products

• 918144-06-6 C₁₃H₁₃N₃O₂ 
• 1229012-58-1 3-(4-isopropyl-[1,2,3]thiadiazol-5-yl)-N-(5-methyl-pyrazin-2-ylmethyl)-5-(5-methyl-pyridin-2-yl)-benzamide 
• 1202699-08-8 N-{[1-cyclohexyl-4,6-dihydroxy-5-({[(5-methyl-2-pyrazinyl)methyl]amino}carbonyl)-2-oxo-1,2-dihydro-3-pyridinyl]carbonyl}glycine 
• 769955-36-4 JAC₀₁₁₇₉-7 
• 1138549-36-6 2-(4-methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide 
• 1072804-42-2 2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methyl-N-((5-methylpyrazin-2-yl)methyl)thiazole-5-carboxamide 
• 1611472-28-6 8-(4-chlorophenyl)-N-((5-methylpyrazin-2-yl)methyl)-1,6-naphthyridine-2-carboxamide 
• 1421921-72-3 2-[4-({(E)-[ethyl(methyl)amino]methylidene}amino)-2,5-dimethylbenzyl]-N-[(5-methylpyrazin-2-yl)methyl]-1,3-thiazole-4-carboxamide 

Relevant academic research and scientific papers

He pyrrole testsamine synonym, preparation method and its application

The invention relates to the field of medicinal chemistry and particularly relates to picotamide analogues (I), a preparation method and a pharmaceutical composition containing the picotamide analogues, wherein R represents hydrogen, 3, 5, 6- trimethyl, 5-methyl or 6-methyl. The picotamide analogues provided by the invention can be used for treating or preventing thromboembolic diseases.

OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula 1: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity

We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (±)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.